Skip to main content
Top
Published in: Clinical and Experimental Nephrology 1/2012

01-02-2012 | Review Article

The roles of V1a vasopressin receptors in blood pressure homeostasis: a review of studies on V1a receptor knockout mice

Authors: Yoko Fujiwara, Akito Tanoue, Gozoh Tsujimoto, Taka-aki Koshimizu

Published in: Clinical and Experimental Nephrology | Issue 1/2012

Login to get access

Abstract

A prompt rise in blood pressure occurs when arginine-vasopressin is administered in quantities adequate to activate vascular V1a subtype vasopressin receptors. However, it has been controversial whether the endogenous vasopressin-V1a system contributes to the maintenance of basal blood pressure during normal development and aging. Mutant mice lacking the V1a receptor gene (V1a−/−) show significantly lower blood pressure compared to control mice, without a notable change in heart rate. In V1a−/− mice, arterial baroreceptor reflexes were attenuated due to malfunctioning baroreflex center, and the mice’s circulating blood volume was significantly reduced. In line with this reduction in circulating blood volume, adrenocortical hormone release was attenuated; plasma aldosterone levels were reduced and adrenocorticotropic hormone-stimulated corticosteroid release was attenuated. In addition, V1a receptor expression was detected in macula densa cells of the kidneys, which may have facilitated renin production from the juxtaglomerular cells. Deletion of the V1a receptor appears to impact the renin–angiotensin–aldosterone system. Studies on V1a−/− mice revealed that non-vascular V1a receptors in the central nervous system and peripheral tissues play critical roles in the maintenance of blood pressure homeostasis.
Literature
1.
go back to reference Kovacs GL, Bohus B, Versteeg DH, de Kloet ER, de Wied D. Effect of oxytocin and vasopressin on memory consolidation: sites of action and catecholaminergic correlates after local microinjection into limbic-midbrain structures. Brain Res. 1979;175(2):303–14.PubMedCrossRef Kovacs GL, Bohus B, Versteeg DH, de Kloet ER, de Wied D. Effect of oxytocin and vasopressin on memory consolidation: sites of action and catecholaminergic correlates after local microinjection into limbic-midbrain structures. Brain Res. 1979;175(2):303–14.PubMedCrossRef
2.
go back to reference Kribben A, Wieder ED, Li X, van Putten V, Granot Y, Schrier RW, Nemenoff RA. AVP-induced activation of MAP kinase in vascular smooth muscle cells is mediated through protein kinase C. Am J Physiol. 1993;265(4 Pt 1):C939–45.PubMed Kribben A, Wieder ED, Li X, van Putten V, Granot Y, Schrier RW, Nemenoff RA. AVP-induced activation of MAP kinase in vascular smooth muscle cells is mediated through protein kinase C. Am J Physiol. 1993;265(4 Pt 1):C939–45.PubMed
3.
go back to reference Rivier C, Vale W. Modulation of stress-induced ACTH release by corticotropin-releasing factor, catecholamines and vasopressin. Nature. 1983;305(5932):325–7.PubMedCrossRef Rivier C, Vale W. Modulation of stress-induced ACTH release by corticotropin-releasing factor, catecholamines and vasopressin. Nature. 1983;305(5932):325–7.PubMedCrossRef
4.
go back to reference Hems DA, Whitton PD. Stimulation by vasopressin of glycogen breakdown and gluconeogenesis in the perfused rat liver. Biochem J. 1973;136(3):705–9.PubMed Hems DA, Whitton PD. Stimulation by vasopressin of glycogen breakdown and gluconeogenesis in the perfused rat liver. Biochem J. 1973;136(3):705–9.PubMed
5.
go back to reference Nielsen S, DiGiovanni SR, Christensen EI, Knepper MA, Harris HW. Cellular and subcellular immunolocalization of vasopressin-regulated water channel in rat kidney. Proc Natl Acad Sci USA. 1993;90(24):11663–7.PubMedCrossRef Nielsen S, DiGiovanni SR, Christensen EI, Knepper MA, Harris HW. Cellular and subcellular immunolocalization of vasopressin-regulated water channel in rat kidney. Proc Natl Acad Sci USA. 1993;90(24):11663–7.PubMedCrossRef
6.
7.
go back to reference Thibonnier M, Coles P, Thibonnier A, Shoham M. Molecular pharmacology and modeling of vasopressin receptors. Prog Brain Res. 2002;139:179–96.PubMedCrossRef Thibonnier M, Coles P, Thibonnier A, Shoham M. Molecular pharmacology and modeling of vasopressin receptors. Prog Brain Res. 2002;139:179–96.PubMedCrossRef
8.
go back to reference Ali F, Guglin M, Vaitkevicius P, Ghali JK. Therapeutic potential of vasopressin receptor antagonists. Drugs. 2007;67(6):847–58.PubMedCrossRef Ali F, Guglin M, Vaitkevicius P, Ghali JK. Therapeutic potential of vasopressin receptor antagonists. Drugs. 2007;67(6):847–58.PubMedCrossRef
9.
go back to reference Share L. Role of vasopressin in cardiovascular regulation. Physiol Rev. 1988;68(4):1248–84.PubMed Share L. Role of vasopressin in cardiovascular regulation. Physiol Rev. 1988;68(4):1248–84.PubMed
10.
go back to reference Liard JF. Vasopressin in cardiovascular control: role of circulating vasopressin. Clin Sci (Lond). 1984;67(5):473–81. Liard JF. Vasopressin in cardiovascular control: role of circulating vasopressin. Clin Sci (Lond). 1984;67(5):473–81.
11.
go back to reference Erlenbach I, Wess J. Molecular basis of V2 vasopressin receptor/Gs coupling selectivity. J Biol Chem. 1998;273(41):26549–58.PubMedCrossRef Erlenbach I, Wess J. Molecular basis of V2 vasopressin receptor/Gs coupling selectivity. J Biol Chem. 1998;273(41):26549–58.PubMedCrossRef
12.
go back to reference Ostrowski NL, Young WS 3rd, Knepper MA, Lolait SJ. Expression of vasopressin V1a and V2 receptor messenger ribonucleic acid in the liver and kidney of embryonic, developing, and adult rats. Endocrinology. 1993;133(4):1849–59.PubMedCrossRef Ostrowski NL, Young WS 3rd, Knepper MA, Lolait SJ. Expression of vasopressin V1a and V2 receptor messenger ribonucleic acid in the liver and kidney of embryonic, developing, and adult rats. Endocrinology. 1993;133(4):1849–59.PubMedCrossRef
13.
go back to reference Klussmann E, Maric K, Wiesner B, Beyermann M, Rosenthal W. Protein kinase A anchoring proteins are required for vasopressin-mediated translocation of aquaporin-2 into cell membranes of renal principal cells. J Biol Chem. 1999;274(8):4934–8.PubMedCrossRef Klussmann E, Maric K, Wiesner B, Beyermann M, Rosenthal W. Protein kinase A anchoring proteins are required for vasopressin-mediated translocation of aquaporin-2 into cell membranes of renal principal cells. J Biol Chem. 1999;274(8):4934–8.PubMedCrossRef
14.
go back to reference Burrell LM, Phillips PA, Risvanis J, Aldred KL, Hutchins AM, Johnston CI. Attenuation of genetic hypertension after short-term vasopressin V1A receptor antagonism. Hypertension. 1995;26(5):828–34.PubMed Burrell LM, Phillips PA, Risvanis J, Aldred KL, Hutchins AM, Johnston CI. Attenuation of genetic hypertension after short-term vasopressin V1A receptor antagonism. Hypertension. 1995;26(5):828–34.PubMed
15.
go back to reference Burrell LM, Phillips PA, Stephenson JM, Risvanis J, Rolls KA, Johnston CI. Blood pressure-lowering effect of an orally active vasopressin V1 receptor antagonist in mineralocorticoid hypertension in the rat. Hypertension. 1994;23(6 Pt 1):737–43.PubMed Burrell LM, Phillips PA, Stephenson JM, Risvanis J, Rolls KA, Johnston CI. Blood pressure-lowering effect of an orally active vasopressin V1 receptor antagonist in mineralocorticoid hypertension in the rat. Hypertension. 1994;23(6 Pt 1):737–43.PubMed
16.
go back to reference Jackson EK. Vasopressin and other agents affecting the renal conservation of water. In: Hardman JG, Limbird LE, Goodman Gilman A, editors. Goodman & Gilman’s the pharmacological basis of therapeutics. MacGraw-Hill: New York; 1996. p. 715–31. Jackson EK. Vasopressin and other agents affecting the renal conservation of water. In: Hardman JG, Limbird LE, Goodman Gilman A, editors. Goodman & Gilman’s the pharmacological basis of therapeutics. MacGraw-Hill: New York; 1996. p. 715–31.
17.
go back to reference Yamamura Y, Ogawa H, Chihara T, Kondo K, Onogawa T, Nakamura S, Mori T, Tominaga M, Yabuuchi Y. OPC-21268, an orally effective, nonpeptide vasopressin V1 receptor antagonist. Science. 1991;252(5005):572–4.PubMedCrossRef Yamamura Y, Ogawa H, Chihara T, Kondo K, Onogawa T, Nakamura S, Mori T, Tominaga M, Yabuuchi Y. OPC-21268, an orally effective, nonpeptide vasopressin V1 receptor antagonist. Science. 1991;252(5005):572–4.PubMedCrossRef
18.
go back to reference Serradeil-Le Gal C, Wagnon J, Garcia C, Lacour C, Guiraudou P, Christophe B, Villanova G, Nisato D, Maffrand JP, Le Fur G, et al. Biochemical and pharmacological properties of SR 49059, a new, potent, nonpeptide antagonist of rat and human vasopressin V1a receptors. J Clin Invest. 1993;92(1):224–31. Serradeil-Le Gal C, Wagnon J, Garcia C, Lacour C, Guiraudou P, Christophe B, Villanova G, Nisato D, Maffrand JP, Le Fur G, et al. Biochemical and pharmacological properties of SR 49059, a new, potent, nonpeptide antagonist of rat and human vasopressin V1a receptors. J Clin Invest. 1993;92(1):224–31.
19.
go back to reference Chapman JT, Hreash F, Laycock JF, Walter SJ. The cardiovascular effects of vasopressin after haemorrhage in anaesthetized rats. J Physiol. 1986;375:421–34.PubMed Chapman JT, Hreash F, Laycock JF, Walter SJ. The cardiovascular effects of vasopressin after haemorrhage in anaesthetized rats. J Physiol. 1986;375:421–34.PubMed
20.
go back to reference Sladek CD, Blair ML, Sterling C, Mangiapane ML. Attenuation of spontaneous hypertension in rats by a vasopressin antagonist. Hypertension. 1988;12(5):506–12.PubMed Sladek CD, Blair ML, Sterling C, Mangiapane ML. Attenuation of spontaneous hypertension in rats by a vasopressin antagonist. Hypertension. 1988;12(5):506–12.PubMed
21.
go back to reference Valtin H. The discovery of the Brattleboro rat, recommended nomenclature, and the question of proper controls. Ann N Y Acad Sci. 1982;394:1–9.PubMedCrossRef Valtin H. The discovery of the Brattleboro rat, recommended nomenclature, and the question of proper controls. Ann N Y Acad Sci. 1982;394:1–9.PubMedCrossRef
22.
go back to reference Padfield PL, Brown JJ, Lever AF, Morton JJ, Robertson JI. Blood pressure in acute and chronic vasopressin excess: studies of malignant hypertension and the syndrome of inappropriate antidiuretic hormone secretion. N Engl J Med. 1981;304(18):1067–70.PubMedCrossRef Padfield PL, Brown JJ, Lever AF, Morton JJ, Robertson JI. Blood pressure in acute and chronic vasopressin excess: studies of malignant hypertension and the syndrome of inappropriate antidiuretic hormone secretion. N Engl J Med. 1981;304(18):1067–70.PubMedCrossRef
23.
go back to reference Koshimizu TA, Nasa Y, Tanoue A, Oikawa R, Kawahara Y, Kiyono Y, Adachi T, Tanaka T, Kuwaki T, Mori T, Takeo S, Okamura H, Tsujimoto G. V1a vasopressin receptors maintain normal blood pressure by regulating circulating blood volume and baroreflex sensitivity. Proc Natl Acad Sci USA. 2006;103(20):7807–12.PubMedCrossRef Koshimizu TA, Nasa Y, Tanoue A, Oikawa R, Kawahara Y, Kiyono Y, Adachi T, Tanaka T, Kuwaki T, Mori T, Takeo S, Okamura H, Tsujimoto G. V1a vasopressin receptors maintain normal blood pressure by regulating circulating blood volume and baroreflex sensitivity. Proc Natl Acad Sci USA. 2006;103(20):7807–12.PubMedCrossRef
24.
go back to reference Braunwald E, Wagner HN Jr. The pressor effect of the antidiuretic principle of the posterior pituitary in orthostatic hypotension. J Clin Invest. 1956;35(12):1412–8.PubMedCrossRef Braunwald E, Wagner HN Jr. The pressor effect of the antidiuretic principle of the posterior pituitary in orthostatic hypotension. J Clin Invest. 1956;35(12):1412–8.PubMedCrossRef
25.
go back to reference Aoyagi T, Birumachi J, Hiroyama M, Fujiwara Y, Sanbe A, Yamauchi J, Tanoue A. Alteration of glucose homeostasis in V1a vasopressin receptor-deficient mice. Endocrinology. 2007;148(5):2075–84.PubMedCrossRef Aoyagi T, Birumachi J, Hiroyama M, Fujiwara Y, Sanbe A, Yamauchi J, Tanoue A. Alteration of glucose homeostasis in V1a vasopressin receptor-deficient mice. Endocrinology. 2007;148(5):2075–84.PubMedCrossRef
26.
go back to reference Aoyagi T, Izumi Y, Hiroyama M, Matsuzaki T, Yasuoka Y, Sanbe A, Miyazaki H, Fujiwara Y, Nakayama Y, Kohda Y, Yamauchi J, Inoue T, Kawahara K, Saito H, Tomita K, Nonoguchi H, Tanoue A. Vasopressin regulates the renin–angiotensin–aldosterone system via V1a receptors in macula densa cells. Am J Physiol Renal Physiol. 2008;295(1):F100–7.PubMedCrossRef Aoyagi T, Izumi Y, Hiroyama M, Matsuzaki T, Yasuoka Y, Sanbe A, Miyazaki H, Fujiwara Y, Nakayama Y, Kohda Y, Yamauchi J, Inoue T, Kawahara K, Saito H, Tomita K, Nonoguchi H, Tanoue A. Vasopressin regulates the renin–angiotensin–aldosterone system via V1a receptors in macula densa cells. Am J Physiol Renal Physiol. 2008;295(1):F100–7.PubMedCrossRef
27.
go back to reference Guillon G, Trueba M, Joubert D, Grazzini E, Chouinard L, Cote M, Payet MD, Manzoni O, Barberis C, Robert M, et al. Vasopressin stimulates steroid secretion in human adrenal glands: comparison with angiotensin-II effect. Endocrinology. 1995;136(3):1285–95. Guillon G, Trueba M, Joubert D, Grazzini E, Chouinard L, Cote M, Payet MD, Manzoni O, Barberis C, Robert M, et al. Vasopressin stimulates steroid secretion in human adrenal glands: comparison with angiotensin-II effect. Endocrinology. 1995;136(3):1285–95.
28.
go back to reference Perraudin V, Delarue C, Lefebvre H, Do Rego JL, Vaudry H, Kuhn JM. Evidence for a role of vasopressin in the control of aldosterone secretion in primary aldosteronism: in vitro and in vivo studies. J Clin Endocrinol Metab. 2006;91(4):1566–72.PubMedCrossRef Perraudin V, Delarue C, Lefebvre H, Do Rego JL, Vaudry H, Kuhn JM. Evidence for a role of vasopressin in the control of aldosterone secretion in primary aldosteronism: in vitro and in vivo studies. J Clin Endocrinol Metab. 2006;91(4):1566–72.PubMedCrossRef
29.
go back to reference Birumachi J, Hiroyama M, Fujiwara Y, Aoyagi T, Sanbe A, Tanoue A. Impaired arginine-vasopressin-induced aldosterone release from adrenal gland cells in mice lacking the vasopressin V1A receptor. Eur J Pharmacol. 2007;566(1–3):226–30.PubMedCrossRef Birumachi J, Hiroyama M, Fujiwara Y, Aoyagi T, Sanbe A, Tanoue A. Impaired arginine-vasopressin-induced aldosterone release from adrenal gland cells in mice lacking the vasopressin V1A receptor. Eur J Pharmacol. 2007;566(1–3):226–30.PubMedCrossRef
30.
go back to reference Gerber JG, Keller RT, Nies AS. Prostaglandins and renin release: the effect of PGI2, PGE2, and 13, 14-dihydro PGE2 on the baroreceptor mechanism of renin release in the dog. Circ Res. 1979;44(6):796–9.PubMed Gerber JG, Keller RT, Nies AS. Prostaglandins and renin release: the effect of PGI2, PGE2, and 13, 14-dihydro PGE2 on the baroreceptor mechanism of renin release in the dog. Circ Res. 1979;44(6):796–9.PubMed
31.
go back to reference Jensen BL, Schmid C, Kurtz A. Prostaglandins stimulate renin secretion and renin mRNA in mouse renal juxtaglomerular cells. Am J Physiol. 1996;271(3 Pt 2):F659–69.PubMed Jensen BL, Schmid C, Kurtz A. Prostaglandins stimulate renin secretion and renin mRNA in mouse renal juxtaglomerular cells. Am J Physiol. 1996;271(3 Pt 2):F659–69.PubMed
32.
go back to reference Kurtz A, Wagner C. Role of nitric oxide in the control of renin secretion. Am J Physiol. 1998;275(6 Pt 2):F849–62.PubMed Kurtz A, Wagner C. Role of nitric oxide in the control of renin secretion. Am J Physiol. 1998;275(6 Pt 2):F849–62.PubMed
33.
go back to reference Malayan SA, Ramsay DJ, Keil LC, Reid IA. Effects of increases in plasma vasopressin concentration on plasma renin activity, blood pressure, heart rate, and plasma corticosteroid concentration in conscious dogs. Endocrinology. 1980;107(6):1899–904.PubMedCrossRef Malayan SA, Ramsay DJ, Keil LC, Reid IA. Effects of increases in plasma vasopressin concentration on plasma renin activity, blood pressure, heart rate, and plasma corticosteroid concentration in conscious dogs. Endocrinology. 1980;107(6):1899–904.PubMedCrossRef
34.
go back to reference Merrill DC, Cowley AW Jr. Chronic effects of vasopressin on plasma renin activity in sodium-restricted dogs. Am J Physiol. 1986;250(3 Pt 2):F460–9.PubMed Merrill DC, Cowley AW Jr. Chronic effects of vasopressin on plasma renin activity in sodium-restricted dogs. Am J Physiol. 1986;250(3 Pt 2):F460–9.PubMed
35.
go back to reference Schwartz J, Reid IA. Role of the vasoconstrictor and antidiuretic activities of vasopressin in inhibition of renin secretion in conscious dogs. Am J Physiol. 1986;250(1 Pt 2):F92–6.PubMed Schwartz J, Reid IA. Role of the vasoconstrictor and antidiuretic activities of vasopressin in inhibition of renin secretion in conscious dogs. Am J Physiol. 1986;250(1 Pt 2):F92–6.PubMed
36.
go back to reference Arai Y, Fujimori A, Sasamata M, Miyata K. New topics in vasopressin receptors and approach to novel drugs: research and development of conivaptan hydrochloride (YM087), a drug for the treatment of hyponatremia. J Pharmacol Sci. 2009;109(1):53–9.PubMedCrossRef Arai Y, Fujimori A, Sasamata M, Miyata K. New topics in vasopressin receptors and approach to novel drugs: research and development of conivaptan hydrochloride (YM087), a drug for the treatment of hyponatremia. J Pharmacol Sci. 2009;109(1):53–9.PubMedCrossRef
37.
go back to reference Zeltser D, Rosansky S, van Rensburg H, Verbalis JG, Smith N. Assessment of the efficacy and safety of intravenous conivaptan in euvolemic and hypervolemic hyponatremia. Am J Nephrol. 2007;27(5):447–57.PubMedCrossRef Zeltser D, Rosansky S, van Rensburg H, Verbalis JG, Smith N. Assessment of the efficacy and safety of intravenous conivaptan in euvolemic and hypervolemic hyponatremia. Am J Nephrol. 2007;27(5):447–57.PubMedCrossRef
38.
go back to reference Yeates KE, Morton AR. Vasopressin antagonists: role in the management of hyponatremia. Am J Nephrol. 2006;26(4):348–55.PubMedCrossRef Yeates KE, Morton AR. Vasopressin antagonists: role in the management of hyponatremia. Am J Nephrol. 2006;26(4):348–55.PubMedCrossRef
39.
go back to reference Ghali JK, Koren MJ, Taylor JR, Brooks-Asplund E, Fan K, Long WA, Smith N. Efficacy and safety of oral conivaptan: a V1A/V2 vasopressin receptor antagonist, assessed in a randomized, placebo-controlled trial in patients with euvolemic or hypervolemic hyponatremia. J Clin Endocrinol Metab. 2006;91(6):2145–52.PubMedCrossRef Ghali JK, Koren MJ, Taylor JR, Brooks-Asplund E, Fan K, Long WA, Smith N. Efficacy and safety of oral conivaptan: a V1A/V2 vasopressin receptor antagonist, assessed in a randomized, placebo-controlled trial in patients with euvolemic or hypervolemic hyponatremia. J Clin Endocrinol Metab. 2006;91(6):2145–52.PubMedCrossRef
40.
go back to reference Decaux G, Soupart A, Vassart G. Non-peptide arginine-vasopressin antagonists: the vaptans. Lancet. 2008;371(9624):1624–32.PubMedCrossRef Decaux G, Soupart A, Vassart G. Non-peptide arginine-vasopressin antagonists: the vaptans. Lancet. 2008;371(9624):1624–32.PubMedCrossRef
41.
go back to reference Konstam MA, Gheorghiade M, Burnett JC Jr, Grinfeld L, Maggioni AP, Swedberg K, Udelson JE, Zannad F, Cook T, Ouyang J, Zimmer C, Orlandi C. Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST Outcome Trial. JAMA. 2007;297(12):1319–31.PubMedCrossRef Konstam MA, Gheorghiade M, Burnett JC Jr, Grinfeld L, Maggioni AP, Swedberg K, Udelson JE, Zannad F, Cook T, Ouyang J, Zimmer C, Orlandi C. Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST Outcome Trial. JAMA. 2007;297(12):1319–31.PubMedCrossRef
42.
go back to reference Gheorghiade M, Konstam MA, Burnett JC Jr, Grinfeld L, Maggioni AP, Swedberg K, Udelson JE, Zannad F, Cook T, Ouyang J, Zimmer C, Orlandi C. Short-term clinical effects of tolvaptan, an oral vasopressin antagonist, in patients hospitalized for heart failure: the EVEREST Clinical Status Trials. JAMA. 2007;297(12):1332–43.PubMedCrossRef Gheorghiade M, Konstam MA, Burnett JC Jr, Grinfeld L, Maggioni AP, Swedberg K, Udelson JE, Zannad F, Cook T, Ouyang J, Zimmer C, Orlandi C. Short-term clinical effects of tolvaptan, an oral vasopressin antagonist, in patients hospitalized for heart failure: the EVEREST Clinical Status Trials. JAMA. 2007;297(12):1332–43.PubMedCrossRef
43.
44.
go back to reference Goldsmith SR. Is there a cardiovascular rationale for the use of combined vasopressin V1a/V2 receptor antagonists? Am J Med. 2006;119(7 Suppl 1):S93–6.PubMedCrossRef Goldsmith SR. Is there a cardiovascular rationale for the use of combined vasopressin V1a/V2 receptor antagonists? Am J Med. 2006;119(7 Suppl 1):S93–6.PubMedCrossRef
Metadata
Title
The roles of V1a vasopressin receptors in blood pressure homeostasis: a review of studies on V1a receptor knockout mice
Authors
Yoko Fujiwara
Akito Tanoue
Gozoh Tsujimoto
Taka-aki Koshimizu
Publication date
01-02-2012
Publisher
Springer Japan
Published in
Clinical and Experimental Nephrology / Issue 1/2012
Print ISSN: 1342-1751
Electronic ISSN: 1437-7799
DOI
https://doi.org/10.1007/s10157-011-0497-y

Other articles of this Issue 1/2012

Clinical and Experimental Nephrology 1/2012 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.